Register Free
UK’s Clinical Knowledge Hub • NICE • MHRA • NHS England

Clinical intelligence,
instantly accessible.

Search UK and European guidelines, safety updates, clinical trials, drug mechanisms and CPD resources in one evidence-based platform.

162+ NICE Guidelines
1003+ Clinical Trials
379+ News Articles
Open Education
Browse Guidelines → Explore Drug Science
Safety Alert Finasteride and Dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction 11 May 2026
All Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases Nephrology Haematology
Explore by Specialty All specialties →
Oncology 434 Cardiology / Cardiovascular 212 Respiratory / COPD / Asthma 133 Infectious Disease 78 Gastroenterology 58 Neurology 57 Rheumatology 57 Diabetes / Metabolic 56 Mental Health / Psychiatry 39 Women's Health 35 Dermatology 23 Men's Health 12 Rare Diseases 5 Nephrology 1 Haematology 1
Trial clinicaltrialsgov

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

Satralizumab injection tested for treating thyroid eye disease by blocking inflammation.

Phase 3 Active Not Recruiting NCT06106828
Start Date
Nov 2023
Est. Completion
Jul 2025
14 May 2026 Read article →
Latest
Trial clinicaltrialsgov
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
14 May 2026
Trial clinicaltrialsgov
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
14 May 2026
Clinical Intelligence
Guidelines
View all guidelines →
NICE Neurology
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)
  • ●**Oxybutynin is effective for neurogenic detrusor overactivity** in patients aged 6+ years…
  • ●**Monitor for anticholinergic side effects** including dry mouth, constipation, urinary retention, and…
07 May 2026
NICE Cardiology / Cardiovascular
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
  • ●**Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to…
  • ●**Treatment requires baseline and regular monitoring of renal function, lipids, and cardiovascular…
07 May 2026
NICE Oncology
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment
  • ●Zanidatamab is recommended by NICE as an option for HER2-positive advanced biliary…
  • ●HER2 status must be confirmed through appropriate testing before considering zanidatamab treatment,…
07 May 2026
Trial Radar
Clinical Trials
Trial collections View all trials →
PHASE3 RECRUITING
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
ADOPT-lung is an international, multicentre, open-label randomised phase III trial. Protocol treatment consists of 3-4 cycles of neoadjuvant durvalumab in…
Oncology
PHASE1 RECRUITING
A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
The present phase 1b/2 randomised, double-blind, placebo-controlled, two-part study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary…
Respiratory / COPD / Asthma
NA RECRUITING
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
The purpose of this research study is to determine if the Enterra® Therapy System can decrease nausea and vomiting symptoms…
Respiratory / COPD / Asthma
Drug Science
Molecular Mechanisms
Starter packs Explore mechanisms →
Mechanism Cardiology / Cardiovascular
HMG-CoA Reductase — Statins
• HMG-CoA Reductase — Statins is a clinically relevant Drug Science explainer. • 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase catalyses the rate-limiting step in the mevalonate pathway — the…
Open explainer →
Mechanism Gastroenterology
S1P Receptor Modulation — MS/IBD
• S1P Receptor Modulation — MS/IBD is a clinically relevant Drug Science explainer. • Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite generated by sphingosine kinase-mediated phosphorylation of sphingosine,…
Open explainer →
Mechanism Dermatology
BRAF/MEK Pathway — Melanoma
• BRAF/MEK Pathway — Melanoma is a clinically relevant Drug Science explainer. • The MAPK signalling cascade (RAS-RAF-MEK-ERK) transmits extracellular growth signals from receptor tyrosine kinases to the…
Open explainer →
Latest Updates
Clinical News
View all news →
UKHSA Infectious Disease 14 May 2026
New HIV report shows progress but inequalities persist in access to testing, PrEP and early diagnosis
HIV testing uptake lowest among Black African heterosexual women in sexual health services
Read article →
BBC Health 14 May 2026
‘We’re right on track,’ says Streeting as key target for hospital waiting times hit
BBC Health 14 May 2026
What sugar does to your body
BBC Health 13 May 2026
How do weight-loss drugs like Mounjaro and Wegovy work?
CPD Accredited
Podcasts & Education
View all podcasts →
Upcoming 0.5 CPD
Drug Interactions: Mechanisms, Red Flags and Practical Management
Dr Anzal Qurbain
Upcoming 0.5 CPD
Polypharmacy and Deprescribing: When Less Is More
Dr Anzal Qurbain
Upcoming 0.5 CPD
Prescribing in Pregnancy: Safe Choices, Teratogens and Risk Communication
Dr Anzal Qurbain
162+Guidelines
1003+Clinical Trials
379+News Articles
15Specialties